Sigma-Aldrich to sell branded solvents and inorganics business in EU to Honeywell

Published: 23-Oct-2015
Ingredients Finance

Part of commitment made to European Commission to receive approval for sale to Merck


Sigma-Aldrich has agreed to sell its branded solvents and inorganics business in the EEA to Honeywell. The sale also includes global rights to the company's Fluka brand.

The sale should fulfil the commitment the company made to the European Union in order to receive final approval for its sale to Merck KGaA of Darmstadt, Germany.

Merck will now submit the Honeywell agreement to the European Commission, which has to approve the transaction for the acquisition of Sigma-Aldrich to be completed.

The European Commission provided conditional approval of Merck's acquisition of Sigma-Aldrich on 15 June.

The two companies announced the US$27bn deal in September 2014.

  • Companies:
  • Merck Electronics KGaA
See more

You may also like

Ingredients

Merck expands granulated excipient line for pharma products

Read more
The company has launched a multi-compendial excipient with broad application in both pharma and biopharma

Trending Articles

  1. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  2. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  5. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Merck expands granulated excipient line for pharma products

The company has launched a multi-compendial excipient with broad application in both pharma and biopharma
Manufacturing

MilliporeSigma adds full viral vector contract services with new platform

This new launch has made it one of the first CDMOs and technology developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development
Manufacturing

Merck opens $63m CDMO facility to handle HPAPIs

The industry expert has announced that its Life Science business sector has doubled its highly potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of this facility
Research & Development

eTheRNA announces mRNA research agreement with Merck

The ongoing pandemic has underlined the capability for mRNA vaccines as a therapeutic modality
Manufacturing

Merck expands technology and capacity for ADC manufacturing

“ADCs have experienced remarkable growth, with commercially approved ADCs tripling in the past three years”
Finance

Merck opens viral vector CDMO facility in Carlsbad

This is the company’s second Carlsbad, California-based facility to serve cell and gene therapy customers
Research & Development

BioMed X and Merck extend research collaboration

The two entered a partnership in 2013 and the resulting research has led to 25 scientific publications
Subscribe now